Compare Organon & Co. Common Stock (OGN) vs Vodafone Group Plc American Depositary Shares (VOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Vodafone Group Plc American Depositary Shares — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Vodafone Group Plc American Depositary Shares trades at $15.51 (market cap $36.02B). The key difference: Vodafone Group Plc American Depositary Shares is far larger — about 10× Organon & Co. Common Stock's market cap, and Vodafone Group Plc American Depositary Shares pays the higher dividend (3.45%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Vodafone Group Plc American Depositary Shares for 5 Days on average.
| OGN | VOD | |
|---|---|---|
Market Cap | $3.62B | $36.02B |
Volume | 2,892,999 | 3,089,821 |
Sector | Health | Media |
52-Week High | $13.81 | $17.68 |
52-Week Low | $5.70 | $11.20 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $11.04B | $81.00B |
Dividend Yield | 0.58% | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
VOD trades at $15.555, up 1.07% today, amid a bearish technical signal. The company reported a net loss of $4.17B for 2025, though revenue grew to $37.45B. Positive cash flow from operations of $15.37B and a low EV/EBITDA of 4.33 suggest underlying value. Recent news highlights Vodafone's strategic focus on 5G rollout and cost synergies in the UK, targeting £1 billion by 2032.
The outlook is mixed; analyst consensus leans buy (48%) with potential from operational improvements, but risks include persistent net losses, high debt, and competitive pressures. The stock's current valuation metrics (P/S 0.82, P/B 0.64) indicate it may be undervalued if turnaround efforts succeed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Vodafone Group Plc American Depositary Shares
Vodafone provides mobile, fixed-line, broadband, and business communications services. It operates across Europe and Africa.
Read more on VOD →
